1-20 of 42
Zi Chen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Updated Results from a Phase 1b study of olverembatinib (HQP1351) combined with lisaftoclax (APG-2575) in pediatric patients with relapsed/refractory Philadelphia Chromosome–Positive acute lymphoblastic leukemia

Free
Jingliao Zhang, Junxia Wang, Huanshan Guo, Tianfeng Liu, Yingchi Zhang, Zi Chen, Wenyu Yang, Hengbang Wang, Yifan Zhai, Xiaofan Zhu
Journal: Blood
Blood (2025) 146 (Supplement 1): 6876.
https://doi.org/10.1182/blood-2025-6876
Published: 2025
Journal Articles

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Free
Keshu Zhou, Tingyu Wang, Ting Niu, Meifang Zheng, Jie Jin, Yang Liang, Rui Huang, Shuangnian Xu, Jianhua Qu, Guohui Cui, Fei Li, Yiming Luo, Ru Feng, Wenzheng Yu, Caixia Li, Zhiling Yan, Xin Zhou, Suijing Wu, Lihong Liu, Yinghua Geng, Jishi Wang, Sujun Gao, Jianfei Fu, Xiaoping Zhang, Chunyan Ji, Qianqian Xiang, Xiongpeng Zhu, Yajing Xu, Li'e Lin, Xiaoyu Zhu, Yuping Zhong, Hongling Peng, Ying Zhao, Hui Zeng, Zhao Wang, Rong Fu, Wenbin Qian, Yingmin Liang, Xiaobing Huang, Yajun Li, Min Yu, Zi Chen, Lei Wang, Lichuang Men, Zhiyan Liang, Shan Zeng, Baoer Lu, Yifan Zhai, Jianyong Li
Journal: Blood
Blood (2025) 146 (Supplement 1): 88.
https://doi.org/10.1182/blood-2025-88
Published: 2025
Journal Articles

Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)

Free
Suning Chen, Yu WU, Jianyu Weng, Cheng Zhang, Hongsheng Zhou, Vadim Doronin, Mei Hong, Ying Wang, Xudong Wei, Iurii Osipov, Yulia Alexeeva, Zi Chen, Yanyan Wang, Lichuang Men, Hengbang Wang, Lixin Jiang, Dengkun Xiong, Dajun Yang, Weili Zhao, Yifan Zhai
Journal: Blood
Blood (2025) 146 (Supplement 1): 1574.
https://doi.org/10.1182/blood-2025-1574
Published: 2025
Journal Articles

Olverembatinib (HQP1351) demonstrates efficacy vs. best available therapy (BAT) in patients (pts) with tyrosine kinase inhibitor (TKI)-resistant chronic-Phase chronic myeloid leukemia (CML-CP) in a registrational randomized Phase 2 trial: Up to 4-year follow-up including patients without T315I mutations

Free
Qian Jiang, Zongru Li, Yanli Zhang, Yu Hu, Weiming Li, Yongping Song, Junmin Li, Li Zhou, Bingcheng LIU, Xiaoli Liu, Na Xu, Suning Chen, Zhenfang LIU, Huangling Zhu, Jie Jin, He Huang, Sixuan Qian, Li Meng, Xin Du, Xielan Zhao, Sujun Gao, Yang Liang, Ming Hou, Wei Wang, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2025) 146 (Supplement 1): 3788.
https://doi.org/10.1182/blood-2025-3788
Published: 2025
Journal Articles

Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients (pts) with chronic Phase-chronic myeloid leukemia (CP-CML)

Free
Li Weiming, Yanli Zhang, Huangling Zhu, Yunfan Yang, Na Xu, Bingcheng LIU, Fang Cheng, Zi Chen, Wei Chu, Yifan Zhai, Yu Hu
Journal: Blood
Blood (2025) 146 (Supplement 1): 3782.
https://doi.org/10.1182/blood-2025-3782
Published: 2025
Journal Articles

Results of the APG2575AU101 Study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax–exposed myeloid malignancies

Free
Tapan Kadia, Patricia Kropf, Michael Leahy, Chong Chyn Chua, Shaun Fleming, Caspian Oliai, John Kwan, Chun Yew Fong, Joshua Richmond, Paul Cannell, James Dugan, Maria Baer, Stephen Ting, Daniel Egan, Zi Chen, Qian Niu, Mingyu Li, Divya Mekala, Zhiyan Liang, Mohammad Ahmad, Yifan Zhai
Journal: Blood
Blood (2025) 146 (Supplement 1): 1641.
https://doi.org/10.1182/blood-2025-1641
Published: 2025
Journal Articles

Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP-CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses

Free
Elias Jabbour, Omer Jamy, Paul B. Koller, Vivian G. Oehler, Maria R. Baer, Elza Lomaia, Anthony M. Hunter, Olga Uspenskaya, Svetlana Samarina, Jorge E. Cortes, Sudipto Mukherjee, Dennis Dong Hwan Kim, Vera Zherebtsova, Vasily Shuvaev, Anna Turkina, Igor Davydkin, Huanshan Guo, Zi Chen, Hengbang Wang, Tommy Fu, Lixin Jiang, Zhihong Yang, Cunlin Wang, Dajun Yang, Yifan Zhai, Hagop Kantarjian
Journal: Blood
Blood (2024) 144 (Supplement 1): 3151.
https://doi.org/10.1182/blood-2024-207139
Published: 2024
Journal Articles

Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to Venetoclax

Free
Matthew S. Davids, Sikander Ailawadhi, Asher A. Chanan-Khan, Boyd Mudenda, Larysa Nogaieva, Iryna Kryachok, Ganna Usenko, Vladimir Ivanov, Olena Kyselova, Tetiana Perekhrestenko, Ivan Muzhychuk, Alexander Myasnikov, Les Lukavetsky, Andrei Proydakov, Olga Uspenskaya, Elena Borisenkova, Paula Marlton, Tanya Siddiqi, Allison M. Winter, Tamila Lysa, Bulat Akhatovich Bakirov, Tommy Fu, Mingyu Li, Mohammad Ahmad, Zi Chen, Zhiyan Liang, Divya J. Mekala, Olena Karpenko, Iurii Osipov, Asit De, Hengbang Wang, Nashat Gabrail, Vinod Ganju, Tatiana Konstantinova, Olga Samoilova, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2024) 144 (Supplement 1): 4614.
https://doi.org/10.1182/blood-2024-207408
Published: 2024
Journal Articles

Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)

Free
Huafeng Wang, Xudong Wei, Yang Liang, Jianyu Weng, Wenjuan He, Chunkang Chang, Suning Chen, Hongbing Ma, Zi Chen, Lichuang Men, Lihui Liu, Xiaohong Tian, Zhang Zhang, Danhua Cong, Dajun Yang, Yifan Zhai, Jie Jin
Journal: Blood
Blood (2024) 144 (Supplement 1): 3202.
https://doi.org/10.1182/blood-2024-205371
Published: 2024
Journal Articles

Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML)

Free
Li Weiming, Yanli Zhang, Huanling Zhu, Yunfan Yang, Na Xu, Bingcheng Liu, Zi Chen, Wei Chu, Yifan Zhai, Yu Hu
Journal: Blood
Blood (2024) 144 (Supplement 1): 480.
https://doi.org/10.1182/blood-2024-204996
Published: 2024
Journal Articles

Safety and Efficacy of Olverembatinib (HQP1351) Combined with Lisaftoclax (APG-2575) in Children and Adolescents with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (R/R Ph + ALL): First Report from a Phase 1 Study

Free
Jingliao Zhang, Junxia Wang, Huanshan Guo, Tianfeng Liu, Xiaoyan Zhang, Ranran Zhang, Min Ruan, Lixian Chang, Xiaoming Liu, Yuanyuan Ren, Xia Chen, Hengbang Wang, Zi Chen, Yingchi Zhang, Yumei Chen, Li Zhang, Ye Guo, Fang Liu, Xiaojuan Chen, Yao Zou, Wenyu Yang, Yifan Zhai, Xiaofan Zhu
Journal: Blood
Blood (2024) 144 (Supplement 1): 1443.
https://doi.org/10.1182/blood-2024-207035
Published: 2024
Journal Articles

Lisaftoclax (APG-2575) Combined with Novel Therapeutic Regimens in Patients (pts) with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (AL) Amyloidosis

Free
Sikander Ailawadhi, Asher A. Chanan-Khan, Jack Khouri, Costas K. Yannakou, Zi Chen, Yanyan Wang, Huanshan Guo, Hengbang Wang, Mingyu Li, Mohammad Ahmad, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2024) 144 (Supplement 1): 1022.
https://doi.org/10.1182/blood-2024-202713
Published: 2024
Journal Articles

Olverembatinib (HQP1351) Demonstrates Efficacy Vs. Best Available Therapy (BAT) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic Myeloid Leukemia Chronic-Phase (CML-CP) in a Registrational Randomized Phase 2 Study

Free
Qian Jiang, Zongru Li, Gongli Zhang, Yu Hu, Weiming Li, Yongping Song, Junmin Li, Li Zhou, Bingcheng Liu, Xiaoli Liu, Na Xu, Suning Chen, Zhenfang Liu, Huanling Zhu, Jie Jin, He Huang, Sixuan Qian, Li Meng, Xin Du, Xielan Zhao, Sujun Gao, Yang Liang, Ming Hou, Wei Wang, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiaojun Huang
Journal: Blood
Blood (2023) 142 (Supplement 1): 869.
https://doi.org/10.1182/blood-2023-187740
Published: 2023
Journal Articles

First Report on the Effects of Lisaftoclax (APG-2575) in Combination with Novel Therapeutic Regimens in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM) or Immunoglobulin Light-Chain (Amyloid Light-Chain [AL]) Amyloidosis

Free
Sikander Ailawadhi, Asher A. Chanan-Khan, Costas K. Yannakou, Simon Gibbs, Jack Khouri, Zi Chen, Huanshan Guo, Mingyu Li, Mohammad Ahmad, Cunlin Wang, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2023) 142 (Supplement 1): 2016.
https://doi.org/10.1182/blood-2023-188122
Published: 2023
Journal Articles

Updated Efficacy and Safety Results of Lisaftoclax (APG-2575) in Patients (Pts) with Heavily Pretreated Chronic Lymphocytic Leukemia (CLL): Pooled Analyses of Two Clinical Trials

Free
Keshu Zhou, Mingyuan Sun, Xu Wei, Shuhua Yi, Junyuan Qi, Weiqi Nian, Guohui Cui, Jishi Wang, Xiaoping Zhang, Hong Cen, Fuling Zhou, Jianying Huang, Huilan Liu, Aizong Shen, Liangquan Geng, Ru Feng, Chongyuan Xu, Wenbin Qian, Fei Li, Lihong Liu, Caixia Li, Xielan Zhao, Jie Jin, Hongmei Jing, Dongmei Ji, Fangfang Lyu, Zi Chen, Lichuang Men, Hengbang Wang, Ke Zhang, Liang Xu, Zhang Zhang, Dajun Yang, Jianxiang Wang, Jianyong Li, Yifan Zhai
Journal: Blood
Blood (2023) 142 (Supplement 1): 1900.
https://doi.org/10.1182/blood-2023-183071
Published: 2023
Journal Articles

Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms

Free
Huafeng Wang, Xudong Wei, Qian Jiang, Wenjun He, Qiubai Li, Yang Liang, Jianyu Weng, Suning Chen, Hongbing Ma, Chukang Chang, Yajing Xu, Qun He, Zi Chen, Lihui Liu, Lichuang Men, Danhua Cong, Zhang Zhang, Dajun Yang, Yifan Zhai, Jie Jin, IV
Journal: Blood
Blood (2023) 142 (Supplement 1): 2925.
https://doi.org/10.1182/blood-2023-188489
Published: 2023
Journal Articles

Unraveling the Evolutionary Paths in Relapsed Early-Stage Follicular Lymphoma Showing Complete Remission

Free
Jasmine Makker, Andrew Wotherspoon, Maria-Myrsini Tzioni, Zi Chen, Francesco Cucco, Ming-Qing Du
Journal: Blood
Blood (2023) 142 (Supplement 1): 5733.
https://doi.org/10.1182/blood-2023-178237
Published: 2023
Journal Articles

Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results

Free
Junyuan Qi, Xudong Wei, Qiubai Li, Chukang Chang, Fuling Zhou, Jianying Huang, Yu Zhang, Chongyuan Xu, Xiaowen Tang, Qian Jiang, Junmin Li, Qun Qin, Qun He, Sujun Gao, Liping Liu, Zi Chen, Min Yu, Jing Wang, Lichuang Men, Hengbang Wang, Mohammad Ahmad, Dajun Yang, Yifan Zhai, Jianxiang Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 5954.
https://doi.org/10.1182/blood-2023-184959
Published: 2023
Journal Articles

Update of Olverembatinib (HQP1351) Overcoming Ponatinib and/or Asciminib Resistance in Patients (Pts) with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)

Free
Elias Jabbour, Hagop M. Kantarjian, Paul B. Koller, Omer Jamy, Vivian G. Oehler, Elza Lomaia, Anthony M. Hunter, Olga Uspenskaya, Svetlana Samarina, Sudipto Mukherjee, Maria R. Baer, Vera Zherebtsova, Vasily Shuvaev, Anna Turkina, Igor Davydkin, Jorge Cortes, Huanshan Guo, Zi Chen, Lei Fu, Hengbang Wang, Lixin Jiang, Cunlin Wang, Dajun Yang, Yifan Zhai
Journal: Blood
Blood (2023) 142 (Supplement 1): 1798.
https://doi.org/10.1182/blood-2023-187744
Published: 2023
Journal Articles

Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation

Free
Qian Jiang, Zongru Li, Yue Hou, Yu Hu, Weiming Li, Xiaoli Liu, Na Xu, Yanli Zhang, Yongping Song, Li Meng, Zhenya Hong, Bingcheng Liu, Yan Li, Suning Chen, Mengxing Xue, Huanling Zhu, He Li, Xin Du, Jin Lou, Xiaohan Zhang, Yang Liang, Yu-Jun Dai, Zi Chen, Qian Niu, Lichuang Men, Dajun Yang, Yifan Zhai, Xiao-Jun Huang
Journal: Blood
Blood (2022) 140 (Supplement 1): 203–204.
https://doi.org/10.1182/blood-2022-170698
Published: 2022